In vitro models have played a key role in the development of new therapeutics for CF. The gold standard model, human bronchial (HBE) epithelial cells is but one of the many available pre-clinical models that demonstrate pathogenesis and are being used to advance therapeutics. In this session, use of in vitro models will be described for clinical prediction of CFTR modulator response, developmental systems that model untreated mutations, and in the development of personalized pathobiology and therapies.
Appraise the evolving landscape of cell-based model that aim to model human disease in the airway.
Define the relative advantage of each model for studying the cellular consequences of different mutations.
Define the relative advantage of each model for therapy development.